Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...